Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients
KJ Freise; AK Jones; ME Verdugo; RM Menon; PC Maciag; AH Salem
Author Information: AbbVie Inc.
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.